Charles River Laboratories International Partners With Magellan Stem Cells For Development, Clinical Advancement Of Stem Cell-Based Therapies, Regenerative Medicine Solutions
Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical
Share
Why It Matters
Charles River partnered with a stem cell company to help develop new medicines. Watch for whether this partnership creates valuable new products or brings in money.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.